Fiera Capital Corp cut its stake in shares of Viking Therapeutics Inc (NASDAQ:VKTX) by 2.6% in the first quarter, Holdings Channel reports. The fund owned 1,422,153 shares of the biotechnology company’s stock after selling 37,621 shares during the period. Fiera Capital Corp’s holdings in Viking Therapeutics were worth $14,136,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also bought and sold shares of VKTX. BlackRock Inc. boosted its position in shares of Viking Therapeutics by 0.4% in the 1st quarter. BlackRock Inc. now owns 4,114,466 shares of the biotechnology company’s stock valued at $40,896,000 after purchasing an additional 15,060 shares during the period. Park West Asset Management LLC increased its position in shares of Viking Therapeutics by 31.8% during the fourth quarter. Park West Asset Management LLC now owns 1,672,507 shares of the biotechnology company’s stock valued at $12,794,000 after purchasing an additional 403,400 shares during the period. Northern Trust Corp increased its position in shares of Viking Therapeutics by 18.5% during the fourth quarter. Northern Trust Corp now owns 728,958 shares of the biotechnology company’s stock valued at $5,576,000 after purchasing an additional 113,995 shares during the period. Columbus Circle Investors boosted its stake in Viking Therapeutics by 90.7% in the 4th quarter. Columbus Circle Investors now owns 652,804 shares of the biotechnology company’s stock valued at $4,994,000 after buying an additional 310,551 shares in the last quarter. Finally, Prosight Management LP boosted its stake in Viking Therapeutics by 127.4% in the fourth quarter. Prosight Management LP now owns 624,000 shares of the biotechnology company’s stock worth $4,774,000 after purchasing an additional 349,590 shares in the last quarter. 63.58% of the stock is owned by institutional investors and hedge funds.
Shares of Viking Therapeutics stock opened at $7.77 on Wednesday. Viking Therapeutics Inc has a 1-year low of $6.97 and a 1-year high of $24.00. The firm has a market cap of $559.81 million, a PE ratio of -19.43 and a beta of 2.38.
Viking Therapeutics (NASDAQ:VKTX) last posted its earnings results on Thursday, May 2nd. The biotechnology company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.02. As a group, equities research analysts forecast that Viking Therapeutics Inc will post -0.41 earnings per share for the current fiscal year.
A number of equities research analysts recently commented on VKTX shares. BidaskClub downgraded Viking Therapeutics from a “sell” rating to a “strong sell” rating in a report on Wednesday, March 6th. Maxim Group cut their price objective on Viking Therapeutics from $28.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, March 14th. Leerink Swann assumed coverage on Viking Therapeutics in a research note on Friday, February 22nd. They set a “market perform” rating and a $10.00 price objective on the stock. William Blair reaffirmed an “outperform” rating on shares of Viking Therapeutics in a report on Friday, March 29th. Finally, Svb Leerink initiated coverage on Viking Therapeutics in a report on Friday, February 22nd. They set a “mkt perform” rating on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $23.48.
ILLEGAL ACTIVITY WARNING: “Fiera Capital Corp Decreases Stake in Viking Therapeutics Inc (NASDAQ:VKTX)” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2019/06/12/fiera-capital-corp-decreases-stake-in-viking-therapeutics-inc-nasdaqvktx.html.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol.
Read More: How much money do you need to begin day trading?
Want to see what other hedge funds are holding VKTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viking Therapeutics Inc (NASDAQ:VKTX).
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.